Pfizer to sell Upjohn business to Mylan Pharma for Rs 180.48 crore

Pfizer to sell Upjohn business to Mylan Pharma for Rs 180.48 crore


Drug firm Ltd on Friday said it has entered into an agreement with Mylan Pharmaceuticals to sell its Upjohn business for Rs 180.48 crore.

The company has entered into a business transfer agreement with Mylan Pharmaceuticals to transfer certain primarily off-patent branded and generic established medicines (Upjohn business) as a going concern to Mylan for a consideration of Rs 180.48 crore, Ltd said in a regulatory filing.

The consideration for the transfer is supported by valuation reports issued by two independent valuers, it added.

“The Upjohn Business comprises six brands which include Lyrica, Viagra, Celebrex, Amlogard, Daxid and Dilantin. These along with related business assets and liabilities will transition to Mylan,” the filing said.

The rationale for the transaction is that Inc, USA on July 29, 2019, announced that it had entered into a definitive agreement to combine its Upjohn business — which consists of off-patented branded and generic established medicines — with Mylan N.V., thereby creating a new global pharmaceutical company, Viatris Inc.

The global transaction was closed in November 2020.

Under the global transaction, six brands currently marketed by Pfizer Ltd in India, viz., Lyrica, Viagra, Celebrex, Amlogard, Daxid and Dilantin, will transition to Mylan Pharmaceuticals.

The transaction in India will be closed upon receipt of regulatory approvals, Pfizer Ltd said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *